Lutein via eye current for advanced age-related macular degeneration
Part of Eyes & vision clinical trials.
This trial tests a new way to deliver lutein (a nutrient for eye health) directly into the eye using a gentle electrical current (iontophoresis). It is for people with advanced age-related macular degeneration (AMD) to see if this treatment can help slow vision loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 55 years old or older
- You have been diagnosed with stage 3 age-related macular degeneration (AMD) in at least one eye
- You have not had eye surgery, laser treatment, or injections in the eye being studied in the last 3 months
- You have not taken lutein or zeaxanthin supplements, or any eye-health supplements, in the past 4 weeks
- You do not have type 1 diabetes or a history of stroke
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to deliver lutein, a nutrient that may help with eye health, directly into the eye using a mild electrical current (called iontophoresis). It is for people with intermediate age-related macular degeneration (AMD), a common cause of vision loss in older adults.
This trial tests a new type of electrical stimulation, called microcurrent therapy, to see if it can help people with a certain form of age-related macular degeneration (AMD) that is not the "wet" kind. The treatment is delivered through an eye patch-like device and may slow vision loss or improve function.
This trial tests a new approach to improve vision in people with end-stage age-related macular degeneration (AMD). It aims to help those whose vision has dropped to a moderate or severe level, even with glasses, and who are not contact lens wearers.
This trial tests a new light-based treatment for intermediate age-related macular degeneration (AMD), a common eye condition that can lead to vision loss. The goal is to see if it is safe and helps slow down the disease.
This study tests a new laser treatment (MacuTherm) for intermediate age-related macular degeneration (iAMD), an eye condition that affects central vision. The study aims to see if this treatment can slow or prevent progression to more advanced stages of the disease.
This trial tests if repeated low-level red-light therapy can help people with dry age-related macular degeneration (AMD), a condition that causes gradual vision loss. The therapy uses red light to potentially slow or improve vision problems.
Hear when a new DML Stage 3 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.